Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2014 1
2015 1
2022 1
2023 3
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.
Moulson R, Law J, Sacher A, Liu G, Shepherd FA, Bradbury P, Eng L, Iczkovitz S, Abbie E, Elia-Pacitti J, Ewara EM, Mokriak V, Weiss J, Pettengell C, Leighl NB. Moulson R, et al. Among authors: elia pacitti j. Curr Oncol. 2024 Apr 2;31(4):1947-1960. doi: 10.3390/curroncol31040146. Curr Oncol. 2024. PMID: 38668049 Free PMC article.
External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.
Boyne DJ, Chua N, Owen C, Joe-Uzuegbu O, Shakir H, Gogna P, Jarada TN, Brenner DR, Elia-Pacitti J, Ewara EM, Cheung WY. Boyne DJ, et al. Among authors: elia pacitti j. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e277-e285. doi: 10.1016/j.clml.2023.05.013. Epub 2023 May 29. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37331847
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers.
O'Sullivan DE, Jarada TN, Yusuf A, Hu LXY, Gogna P, Brenner DR, Abbie E, Rose JB, Eaton K, Elia-Pacitti J, Ewara EM, Pabani A, Cheung WY, Boyne DJ. O'Sullivan DE, et al. Among authors: elia pacitti j. Curr Oncol. 2022 Sep 30;29(10):7198-7208. doi: 10.3390/curroncol29100567. Curr Oncol. 2022. PMID: 36290844 Free PMC article.
Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.
Cheung WY, Carbonell C, Navani V, Sangha RS, Ewara EM, Elia-Pacitti J, Iczkovitz S, Jarada TN, Warkentin MT. Cheung WY, et al. Among authors: elia pacitti j. Curr Oncol. 2024 Jul 31;31(8):4382-4396. doi: 10.3390/curroncol31080327. Curr Oncol. 2024. PMID: 39195310 Free PMC article.
Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma.
Olney HJ, Freeman MA, Stewart DA, Mangel JE, White DJ, Elia-Pacitti JO. Olney HJ, et al. Among authors: elia pacitti jo. Leuk Lymphoma. 2014 Dec;55(12):2754-60. doi: 10.3109/10428194.2014.894190. Epub 2014 Apr 3. Leuk Lymphoma. 2014. PMID: 24528219 Clinical Trial.